PPARα activation improves endothelial dysfunction and reduces fibrosis and portal pressure in cirrhotic rats

Journal of Hepatology

Volumn 56, Issue 5, 2012, Pages 1033-1039

  Rodríguez Vilarrupla, Aina ^a   Laviña, Bàrbara ^a   García Calderó, Héctor ^a   Russo, Lucia ^a   Rosado, Eugenio ^a   Roglans, Núria ^b   Bosch, Jaume ^a   García Pagán, Joan Carles ^a  

^a HOSPITAL CLÍNIC   (Spain)

^b UNIVERSITY OF BARCELONA   (Spain)

Author keywords

COX pathway; Fenofibrate; Nitric oxide; Portal hypertension

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; COLLAGEN TYPE 1; COLLAGENASE 3; CYCLOOXYGENASE 1; ENDOTHELIAL NITRIC OXIDE SYNTHASE; FENOFIBRATE; GELATINASE A; GELATINASE B; MESSENGER RNA; NITRIC OXIDE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; THROMBOXANE B2; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG SCREENING; ENDOTHELIAL DYSFUNCTION; LIVER CIRRHOSIS; LIVER FIBROSIS; LIVER PROTECTION; MALE; MEAN ARTERIAL PRESSURE; NONHUMAN; PORTAL VEIN BLOOD PRESSURE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; STELLATE CELL; VASODILATATION;

ANIMALS; BLOOD PRESSURE; CARBON TETRACHLORIDE; CYCLOOXYGENASE 1; DISEASE MODELS, ANIMAL; ENDOTHELIUM, VASCULAR; FIBROSIS; HYPERTENSION, PORTAL; LIVER; LIVER CIRRHOSIS; MALE; PPAR ALPHA; RATS; RATS, WISTAR; THROMBOXANE B2;

EID: 84859709385     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2011.12.008     Document Type: Article

References (43)

1. Bosch J, Garcia-Pagan JC. Complications of cirrhosis. I. Portal hypertension. J Hepatol 2000;32:141-156. (Pubitemid 30123631)
2. Graupera M, Garcia-Pagan JC, Abraldes JG, Peralta C, Bragulat M, Corominola H, et al. Cyclooxygenase-derived products modulate the increased intrahepatic resistance of cirrhotic rat livers. Hepatology 2003;37:172-181. (Pubitemid 36042158)
3. Graupera M, Garcia-Pagan JC, Pares M, Abraldes JG, Rosello J, Bosch J, et al. Cyclooxygenase-1 inhibition corrects endothelial dysfunction in cirrhotic rat livers. J Hepatol 2003;39:515-521. (Pubitemid 37204650)
4. Wiest R, Groszmann RJ. The paradox of nitric oxide in cirrhosis and portal hypertension: too much, not enough. Hepatology 2002;35:478-491. (Pubitemid 34110432)
5. Auboeuf D, Rieusset J, Fajas L, Vallier P, Frering V, Riou JP, et al. Tissue distribution and quantification of the expression of mRNAs of peroxisome proliferator-activated receptors and liver X receptor-alpha in humans: no alteration in adipose tissue of obese and NIDDM patients. Diabetes 1997;46:1319-1327. (Pubitemid 27315281)
6. Mandard S, Muller M, Kersten S. Peroxisome proliferator-activated receptor alpha target genes. Cell Mol Life Sci 2004;61:393-416. (Pubitemid 38316578)
7. Kersten S, Desvergne B, Wahli W. Roles of PPARs in health and disease. Nature 2000;405:421-424. (Pubitemid 30367411)
8. Robinson E, Grieve DJ. Significance of peroxisome proliferator-activated receptors in the cardiovascular system in health and disease. Pharmacol Ther 2009;122:246-263.
9. Berger J, Moller DE. The mechanisms of action of PPARs. Annu Rev Med 2002;53:409-435. (Pubitemid 34177889)
10. Iglarz M, Touyz RM, Viel EC, Paradis P, Amiri F, Diep QN, et al. Peroxisome proliferator-activated receptor-alpha and receptor-gamma activators prevent cardiac fibrosis in mineralocorticoid-dependent hypertension. Hypertension 2003;42:737-743. (Pubitemid 37237318)
11. Kanie N, Matsumoto T, Kobayashi T, Kamata K. Relationship between peroxisome proliferator-activated receptors (PPAR alpha and PPAR gamma) and endothelium-dependent relaxation in streptozotocin-induced diabetic rats. Br J Pharmacol 2003;140:23-32. (Pubitemid 37175827)
12. Tabernero A, Schoonjans K, Jesel L, Carpusca I, Auwerx J, Andriantsitohaina R. Activation of the peroxisome proliferator-activated receptor alpha protects against myocardial ischaemic injury and improves endothelial vasodilatation. BMC Pharmacol 2002;2:10.
13. Hamblin M, Chang L, Fan Y, Zhang J, Chen YE. PPARs and the cardiovascular system. Antioxid Redox Signal 2009;11:1415-1452.
14. Murakami H, Murakami R, Kambe F, Cao X, Takahashi R, Asai T, et al. Fenofibrate activates AMPK and increases eNOS phosphorylation in HUVEC. Biochem Biophys Res Commun 2006;341:973-978. (Pubitemid 43221761)
15. Okayasu T, Tomizawa A, Suzuki K, Manaka K, Hattori Y. PPARalpha activators upregulate eNOS activity and inhibit cytokine-induced NF-kappaB activation through AMP-activated protein kinase activation. Life Sci 2008;82:884-891.
16. Watts GF, Staels B. Regulation of endothelial nitric oxide synthase by PPAR agonists: molecular and clinical perspectives. Arterioscler Thromb Vasc Biol 2004;24:619-621. (Pubitemid 38451593)
17. Álvarez de Sotomayor M, Mingorance C, Andriantsitohaina R. Fenofibrate improves age-related endothelial dysfunction in rat resistance arteries. Atherosclerosis 2007;193:112-120. (Pubitemid 46776716)
18. Toyama T, Nakamura H, Harano Y, Yamauchi N, Morita A, Kirishima T, et al. PPARalpha ligands activate antioxidant enzymes and suppress hepatic fibrosis in rats. Biochem Biophys Res Commun 2004;324:697-704. (Pubitemid 39345573)
19. Garcia-Caldero H, Rodriguez-Vilarrupla A, Gracia-Sancho J, Divi M, Lavina B, Bosch J, et al. Tempol administration, a superoxide dismutase mimetic, reduces hepatic vascular resistance and portal pressure in cirrhotic rats. J Hepatol 2010;54:660-665.
20. Ichihara S, Obata K, Yamada Y, Nagata K, Noda A, Ichihara G, et al. Attenuation of cardiac dysfunction by a PPAR-alpha agonist is associated with down-regulation of redox-regulated transcription factors. J Mol Cell Cardiol 2006;41:318-329. (Pubitemid 44080222)
21. Alegret M, Ferrando R, Vazquez M, Adzet T, Merlos M, Laguna JC. Relationship between plasma lipids and palmitoyl-CoA hydrolase and synthetase activities with peroxisomal proliferation in rats treated with fibrates. Br J Pharmacol 1994;112:551-556. (Pubitemid 24172899)
22. Sanguino E, Roglans N, Alegret M, Sanchez RM, Vazquez-Carrera M, Laguna JC. Different response of senescent female Sprague-Dawley rats to gemfibrozil and rosiglitazone administration. Exp Gerontol 2005;40:588-598. (Pubitemid 41074805)
23. Abraldes JG, Graupera M, Zafra C, Rodriguez-Vilarruplaa A, Fernandez M, Garcia-Pagan JC, et al. Simvastatin improves sinusoidal endothelial dysfunction in CCl4 cirrhotic rats. J Hepatol 2005;42:62-63.
24. Sanguino E, Ramon M, Michalik L, Wahli W, Alegret M, Sanchez RM, et al. Lack of hypotriglyceridemic effect of gemfibrozil as a consequence of agerelated changes in rat liver PPARalpha. Biochem Pharmacol 2004;67: 157-166. (Pubitemid 37518543)
25. Lavina B, Gracia-Sancho J, Rodriguez-Vilarrupla A, Chu Y, Heistad DD, Bosch J, et al. Superoxide dismutase gene transfer reduces portal pressure in CCl4 cirrhotic rats with portal hypertension. Gut 2009;58:118-125.
26. Gracia-Sancho J, Lavina B, Rodriguez-Vilarrupla A, Garcia-Caldero H, Fernandez M, Bosch J, et al. Increased oxidative stress in cirrhotic rat livers: a potential mechanism contributing to reduced nitric oxide bioavailability. Hepatology 2008;47:1248-1256. (Pubitemid 351547911)
27. Braet F, De Zanger R, Sasaoki T, Baekeland M, Janssens P, Smedsrod B, et al. Assessment of a method of isolation, purification, and cultivation of rat liver sinusoidal endothelial cells. Lab Invest 1994;70:944-952. (Pubitemid 24209496)
28. DeLeve LD, Wang X, Hu L, McCuskey MK, McCuskey RS. Rat liver sinusoidal endothelial cell phenotype is maintained by paracrine and autocrine regulation. Am J Physiol Gastrointest Liver Physiol 2004;287:G757-G763. (Pubitemid 39280433)
29. Abraldes JG, Rodriguez-Vilarrupla A, Graupera M, Zafra C, Garcia-Caldero H, Garcia-Pagan JC, et al. Simvastatin treatment improves liver sinusoidal endothelial dysfunction in CCl(4) cirrhotic rats. J Hepatol 2007;46: 1040-1046. (Pubitemid 46680358)
30. Gracia-Sancho J, Lavina B, Rodriguez-Vilarrupla A, Garcia-Caldero H, Bosch J, Garcia-Pagan JC. Enhanced vasoconstrictor prostanoid production by sinusoidal endothelial cells increases portal perfusion pressure in cirrhotic rat livers. J Hepatol 2007;47:220-227. (Pubitemid 47028585)
31. Mejias M, Garcia-Pras E, Tiani C, Miquel R, Bosch J, Fernandez M. Beneficial effects of sorafenib on splanchnic, intrahepatic, and portocollateral circulations in portal hypertensive and cirrhotic rats. Hepatology 2009;49: 1245-1256.
32. Iwakiri Y, Groszmann RJ. Vascular endothelial dysfunction in cirrhosis. J Hepatol 2007;46:927-934. (Pubitemid 46529052)
33. Hiukka A, Maranghi M, Matikainen N, Taskinen MR. PPARalpha: an emerging therapeutic target in diabetic microvascular damage. Nat Rev Endocrinol 2010;6:454-463.
34. Lefebvre P, Chinetti G, Fruchart JC, Staels B. Sorting out the roles of PPAR alpha in energy metabolism and vascular homeostasis. J Clin Invest 2006;116:571-580. (Pubitemid 43326861)
35. Han SH, Quon MJ, Koh KK. Beneficial vascular and metabolic effects of peroxisome proliferator-activated receptor-alpha activators. Hypertension 2005;46:1086-1092. (Pubitemid 41533006)
36. Bosch J, Berzigotti A, Garcia-Pagan JC, Abraldes JG. The management of portal hypertension: rational basis, available treatments and future options. J Hepatol 2008;48:S68-S92.
37. Nagula S, Jain D, Groszmann RJ, Garcia-Tsao G. Histological-hemodynamic correlation in cirrhosis-a histological classification of the severity of cirrhosis. J Hepatol 2006;44:111-117. (Pubitemid 41772524)
38. Ogata T, Miyauchi T, Sakai S, Irukayama-Tomobe Y, Goto K, Yamaguchi I. Stimulation of peroxisome-proliferator-activated receptor alpha (PPAR alpha) attenuates cardiac fibrosis and endothelin-1 production in pressure- overloaded rat hearts. Clin Sci (Lond) 2002;103:284S-288S. (Pubitemid 35007171)
39. Matei V, Rodriguez-Vilarrupla A, Deulofeu R, Garcia-Caldero H, Fernandez M, Bosch J, et al. Three-day tetrahydrobiopterin therapy increases in vivo hepatic NOS activity and reduces portal pressure in CCl4 cirrhotic rats. J Hepatol 2008;49:192-197.
40. Morales-Ruiz M, Cejudo-Martín P, Fernandez-Varo G, Tugues S, Ros J, Angeli P, et al. Transduction of the liver with activated Akt normalizes portal pressure in cirrhotic rats. Gastroenterology 2003;125:522-531. (Pubitemid 36929434)
41. Remick J, Weintraub H, Setton R, Offenbacher J, Fisher E, Schwartzbard A. Fibrate therapy: an update. Cardiol Rev 2008;16:129-141. (Pubitemid 351549675)
42. Fernandez-Miranda C, Perez-Carreras M, Colina F, Lopez-Alonso G, Vargas C, Solis-Herruzo JA. A pilot trial of fenofibrate for the treatment of non-alcoholic fatty liver disease. Dig Liver Dis 2008;40:200-205. (Pubitemid 351181792)
43. Levy C, Peter JA, Nelson DR, Keach J, Petz J, Cabrera R, et al. Pilot study: fenofibrate for patients with primary biliary cirrhosis and an incomplete response to ursodeoxycholic acid. Aliment Pharmacol Ther 2011;33: 235-242.